Allain, Eric P., et al. "Emerging roles for UDP-glucuronosyltransferases in drug resistance and cancer progression." British journal of cancer 122.9 (2020): 1277-1287.
Anderson, Gail D., and Lingtak-Neander Chan. "Pharmacokinetic drug interactions with tobacco, cannabinoids and smoking cessation products." Clinical pharmacokinetics 55 (2016): 1353-1368.
Baltz, Jacob W., and Lamanh T. Le. "Serotonin syndrome versus cannabis toxicity in the emergency department." Clinical practice and cases in emergency medicine 4.2 (2020): 171.
Bar-Sela, Gil, et al. "Cannabis consumption used by cancer patients during immunotherapy correlates with poor clinical outcome." Cancers 12.9 (2020): 2447.
Boukerche, Faiza, et al. "Serotonin syndrome misdiagnosed in a patient who used a cannabis dab pen." Prim Care Companion CNS Disord 24.2 (2022): 40574.
Brown, Joshua D. "Potential adverse drug events with tetrahydrocannabinol (THC) due to drug–drug interactions." Journal of clinical medicine 9.4 (2020): 919.
Chen, Si, et al. "Metabolism and liver toxicity of cannabidiol." Journal of Environmental Science and Health, Part C 42.3 (2024): 238-254.
Cortopassi, Josh. "Warfarin dose adjustment required after cannabidiol initiation and titration." American Journal of Health-System Pharmacy 77.22 (2020): 1846-1851.
Cox, Emily J., et al. "A marijuana-drug interaction primer: precipitants, pharmacology, and pharmacokinetics." Pharmacology & Therapeutics 201 (2019): 25-38.
Chrobak, Adrian Andrzej, Jarosław Woroń, and Marcin Siwek. "Green rush and red warnings: Retrospective chart review of adverse events of interactions between cannabinoids and psychotropic drugs." Frontiers in Pharmacology 15 (2024): 1500312.
Cuñetti, Leticia, et al. "Chronic pain treatment with cannabidiol in kidney transplant patients in Uruguay." Transplantation proceedings. Vol. 50. No. 2. Elsevier, 2018.
Damkier, Per, et al. "Interaction between warfarin and cannabis." Basic & clinical pharmacology & toxicology 124.1 (2019): 28-31.
Ferretti, Morgan L., et al. "Likelihood of positive urine screens of THC-COOH after daily use of full-spectrum hemp extracts varies as a function of screening criterion used." Therapeutic drug monitoring 45.1 (2023): 126-127.
Flockhart DA, Thacker, D., McDonald, C., Desta, Z. The Flockhart Cytochrome P450 Drug-Drug Interaction Table. Division of Clinical Pharmacology, Indiana University School of Medicine (Updated 2021). https://drug-interactions.medicine.iu.edu. (Accessed December 2024)
Gaston, Tyler E., et al. "Final analysis of potential drug–drug interactions between highly purified cannabidiol and anti‐seizure medications in an open‐label expanded access program." Epilepsia Open 8.4 (2023): 1405-1412.
Geffrey, Alexandra L., et al. "Drug–drug interaction between clobazam and cannabidiol in children with refractory epilepsy." Epilepsia 56.8 (2015): 1246-1251.
Grayson, Leslie, et al. "An interaction between warfarin and cannabidiol, a case report." Epilepsy & behavior case reports 9 (2018): 10-11.
Hauser, Naomi, et al. "High on cannabis and calcineurin inhibitors: a word of warning in an era of legalized marijuana." Case Reports in Transplantation 2016.1 (2016): 4028492.
Lopera, Valentina, Adriana Rodríguez, and Pedro Amariles. "Clinical relevance of drug interactions with cannabis: A systematic review." Journal of Clinical Medicine 11.5 (2022): 1154.
McNamara, Nancy A., et al. "Thrombocytopenia in pediatric patients on concurrent cannabidiol and valproic acid." Epilepsia 61.8 (2020): e85-e89.
Moadel, Daniel, and Keira Chism. "Medical marijuana-induced tacrolimus toxicity." Psychosomatics 60.6 (2019): 603-605.
Nadeem, Zohaib, et al. "Serotonin syndrome and cannabis: A case report." Australasian Psychiatry 32.1 (2024): 100-101.
Nasrin, Shamema, et al. "Cannabinoid metabolites as inhibitors of major hepatic CYP450 enzymes, with implications for cannabis-drug interactions." Drug Metabolism and Disposition 49.12 (2021): 1070-1080.
ncpacbdsource.com (Accessed December 2024)
Patel, Anup D., et al. "Long‐term safety and efficacy of add‐on cannabidiol in patients with Lennox–Gastaut syndrome: Results of a long‐term open‐label extension trial." Epilepsia 62.9 (2021): 2228-2239.
Piper, Brian J., et al. "Immunotherapy and cannabis: a harmful drug interaction or reefer madness?." Cancers 16.7 (2024): 1245.
Smythe, Maureen A., Wendy Wu, and Candice L. Garwood. "Anticoagulant drug–drug interactions with cannabinoids: A systematic review." Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy 43.12 (2023): 1327-1338.
Taha, Tarek, et al. "Cannabis impacts tumor response rate to nivolumab in patients with advanced malignancies." The oncologist 24.4 (2019): 549-554.
Thai, Ching, Bola Tayo, and David Critchley. "A phase 1 open‐label, fixed‐sequence pharmacokinetic drug interaction trial to investigate the effect of cannabidiol on the CYP1A2 Probe caffeine in healthy subjects." Clinical Pharmacology in Drug Development 10.11 (2021): 1279-1289.
Tschoe, Christine, et al. "Serotonin Syndrome with Exposure from Tetrahydrocannabinol: a Case Report to Highlight the Side Effects of Increasing Use of CBD Products (5302)." Neurology 94.15_supplement (2020): 5302.
Vaughn, Samuel E., et al. "The impact of marijuana on antidepressant treatment in adolescents: clinical and pharmacologic considerations." Journal of Personalized Medicine 11.7 (2021): 615.
Vierke, Christopher, et al. "Buprenorphine–cannabis interaction in patients undergoing opioid maintenance therapy." European Archives of Psychiatry and Clinical Neuroscience 271 (2021): 847-856.
Waissengrin, Barliz, et al. "The use of medical cannabis concomitantly with immune checkpoint inhibitors in non-small cell lung cancer: A sigh of relief?." European Journal of Cancer 180 (2023): 52-61.
Watanabe, Kazuhito, et al. "Cytochrome P450 enzymes involved in the metabolism of tetrahydrocannabinols and cannabinol by human hepatic microsomes." Life sciences 80.15 (2007): 1415-1419.
Yamreudeewong, Weeranuj, et al. "Probable interaction between warfarin and marijuana smoking." Annals of Pharmacotherapy 43.7-8 (2009): 1347-1353.
Zhou, Felix, Andreu F. Costa, and Magnus McLeod. "Late presentation of posterior reversible encephalopathy syndrome following liver transplantation in the setting of tacrolimus and cannabis use." Canadian Liver Journal 5.1 (2022): 91-95.
Zhu, Hao-Jie, et al. "Characterization of P-glycoprotein inhibition by major cannabinoids from marijuana." The Journal of pharmacology and experimental therapeutics 317.2 (2006): 850-857.
